Michael Cotten, MD, MHS, co-authored a study about preterm infants and whether a weekly darbepoetin would have greater red cell mass during hospitalization and better neurocognitive outcome at 22 to 26 months' corrected age. The results reveal that the dose and dosing schedule of darbepoetin did not improve cognitive scores of preterm infants at 22 to 26 months' corrected age. However, darbepoetin significantly increased red cell mass, resulting in higher hematocrit values, fewer transfusions, and fewer donor exposures.